Virtus Biotech Clinical Trials ETF
12 hedge funds and large institutions have $9.17M invested in Virtus Biotech Clinical Trials ETF in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
97% more capital inflows, than outflows
Capital inflows: $1.88M | Capital outflows: $954K
20% more funds holding
Funds holding: 10 → 12 (+2)
1.85% more ownership
Funds ownership: 27.44% → 29.29% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$674K |
| 2 |
Advisory Services Network
Atlanta,
Georgia
|
+$591K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$477K |
| 4 |
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$42K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$20K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cardan Capital Partners
Denver,
Colorado
|
-$686K |
| 2 |
Goldman Sachs
New York
|
-$239K |
| 3 |
Avior Wealth Management
Omaha,
Nebraska
|
-$15K |
| 4 |
LPL Financial
San Diego,
California
|
-$13.9K |
BBC Hedge Fund Activity: Q4 2017 in Review
12 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2017, worth a combined $9.17M — up 9.2% from $8.4M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BBC positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $674K. The largest seller was Cardan Capital Partners, exiting entirely with an estimated $686K sold.
- 12 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2017, up from 10 in Q3 2017.
- Funds reported $9.17M of Virtus Biotech Clinical Trials ETF stock for Q4 2017, up 9.2% quarter-over-quarter.
- 4 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2017 and 2 closed out, a net change of +2 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2017 was Jane Street, an estimated $674K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2017 was Cardan Capital Partners, an estimated $686K sold.
Based on aggregated 13F filings for Q4 2017.